Hollinger

EQS-News: Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

Retrieved on: 
Thursday, August 31, 2023
Partnership, PMID, Acute kidney injury, Critical Care (journal), Hollinger, Septic shock, Risk, AKI, Kidney, Korea, Patient, Developed country, Renal replacement therapy, INT, Diagnosis, MDA, Medical device, Dietary supplement, Sepsis

In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.

Key Points: 
  • In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.
  • The current market development agreement aims at enhancing the commercialization of the upcoming assay for penKid and ultimately advancing AKI diagnostics.
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, August 31, 2023 - Boditech Med Inc. (“Boditech”) and SphingoTec GmbH (“SphingoTec”) today announced they have entered into a market development agreement (MDA), building on their previous licensing collaboration for the kidney function biomarker penKid.
  • The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.

EQS-News: ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury

Retrieved on: 
Saturday, April 15, 2023
GFR, Hospice and palliative medicine, Drug development, Therapy, Sepsis, Critical Care (journal), Hollinger, Diagnosis, Glomerular filtration rate, Research, Biomarker, Septic shock, AKI, Dialysis, Incidence, Acute kidney injury, Patient, Risk, Renal replacement therapy, Kidney, Septic, Disease, Medical imaging, Pharmaceutical industry, Hospital

According to the statement, the kidney function biomarker Proenkephalin A 119-159 (penKid) can detect subclinical AKI, enabling early risk prediction for upcoming AKI.

Key Points: 
  • According to the statement, the kidney function biomarker Proenkephalin A 119-159 (penKid) can detect subclinical AKI, enabling early risk prediction for upcoming AKI.
  • Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.
  • Incidence and outcome of subclinical acute kidney injury using penKid in critically ill patients.
  • Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study.

Women-Led Companies Made Outside® and Poppy Hand-Crafted Popcorn® Win Big with Best of Show and Two Gold ADDY Wins at the 2023 American Advertising Federation Awards

Retrieved on: 
Friday, March 10, 2023
Mercedes (name), Silver, American Advertising Federation, Hollinger, Advertising, Food, ADDY, Happiness, Gold, Female, Photography, CPG, Creative industries, Toy, Poppy, Chestnut

CHARLOTTE, N.C., March 9, 2023 /PRNewswire-PRWeb/ -- North Carolina-based creative agency Made Outside has been recognized for its commitment to excellence in creative development and execution at the 2023 American Advertising Awards, also known as the ADDYs, hosted by the American Advertising Federation on February 28 in Charlotte, NC.

Key Points: 
  • The Best in Show award cast a bright spotlight on Made Outside's work for Poppy Hand-Crafted Popcorn, the women-led, Asheville-based gourmet popcorn company specializing in unique flavors and all-natural ingredients.
  • The campaign included a library of brand assets, overhauled creative direction, new photography, product styling, and a Spring 2023 catalog design.
  • The creative agency also won a Gold ADDY for the overall Poppy campaign and a Gold ADDY for the new catalog design.
  • It's been an incredibly rewarding experience to work with another women-founded, women-led company producing results at the highest level."

Good Grades Near Surface, High Grade at Depth

Retrieved on: 
Monday, November 28, 2022
MUX, NW, TSX, Gray fox, Newmont Corporation, Gold, Sulfide, NYSE, Froome, Hollinger, Vein, Mining, Uranium, Dome

Drilling results reveal significant gold mineralization in veins within sedimentary rocks with good gold grades near surface and high-grade gold values encountered at depth.

Key Points: 
  • Drilling results reveal significant gold mineralization in veins within sedimentary rocks with good gold grades near surface and high-grade gold values encountered at depth.
  • At Grey Fox, gold zones are stacked parallel to a southeast-trending regional flexure in the Destor-Porcupine Fault Zone (DPFZ) (Figure 1).
  • Interpreted dimensions of the Gibson target area extends at least 475 m along strike and to at least 300 m depth.
  • In some cases, the veins are brecciated and have crustiform (layered or void-filling) textures that are characteristic of Grey Fox.

EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, November 27, 2022
IVD, Hypertension, Hennigsdorf, Critical Care (journal), Gangwon, Acute kidney injury, Diagnosis, AKI, Partnership, Physician, Renal replacement therapy, Patient, South Korea, Degenerative disease, Biomarker, Critical care, Glomerular filtration rate, Septic shock, Inflammation, Spectrophotometry, Diabetes, Infection, Cancer, Korea, Hollinger, Jean-Louis Vincent, GFR, Kidney, Clinical Chemistry and Laboratory Medicine, Pharmaceutical industry, Medical imaging, Hospital, Sepsis

Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.

Key Points: 
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
  • The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
  • PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
  • Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.

Salt Security Strengthens Executive Leadership Team as Demand for API Security Accelerates

Retrieved on: 
Wednesday, October 26, 2022
People, API, Trust, Reflektion, PALO, Deloitte, Market share, Warner Bros., Zoom Video Communications, Growth, Gap, Riskified, COO, IronSource, Technology, AWS, Arm, Customer success, Hollinger, CrowdStrike, Brand New (Salt-n-Pepa album), Environment, MuleSoft, Management, Video game, Fine chemical, Online shopping, Salt, Google

PALO ALTO, Calif., Oct. 26, 2022 /PRNewswire/ -- Salt Security, the leading API security company, today announced additions to the leadership team to support growth in employees and customers worldwide. Salt has established two new executive leadership roles, naming Renee Hollinger as Chief People Officer and Amelia Forrest Kaye as Vice President of Customer Success. Both Hollinger and Kaye will play pivotal roles in supporting the company's operations and expanding global customer base.

Key Points: 
  • PALO ALTO, Calif., Oct. 26, 2022 /PRNewswire/ -- Salt Security , the leading API security company, today announced additions to the leadership team to support growth in employees and customers worldwide.
  • "As API security risks continue to rise, having their experience shaping our initiatives will ensure that Salt continues our leadership role in this market we've pioneered.
  • "I am excited to join Salt at such a pivotal time in the API security industry," said Hollinger.
  • On October 26, Salt Security will be hosting its second API Security Summit, featuring conversations with AWS, Google, CrowdStrike, MuleSoft, and other partners, customers, and industry experts.

Sidus Space CEO, Carol Craig Chosen as Panelist for the Financial Times “Investing in Space” Summit on June 9, 2022 in London, England

Retrieved on: 
Wednesday, June 8, 2022
Software, Research, Internet, Hardware, Data Management, Technology, Satellite, Science, Engineering, Other Technology, Aerospace, Telecommunications, Manufacturing, Sidus, Nasdaq, ISO 9001:2015, IPO, ITAR, CEO, Female, International business, Financial Times, Government, Bessemer Venture Partners, Technology, Time, NASDAQ, Industry, Spaceflight, Mission, UK Space Agency, Hollinger, Communications satellite

(NASDAQ:SIDU), a Space-as-a-Service satellite company focused on mission critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support, is proud to announce that Sidus Space CEO and Founder Carol Craig has been chosen as a panelist for the Financial Times Investing in Space summit held on June 8-9 in London, England.

Key Points: 
  • (NASDAQ:SIDU), a Space-as-a-Service satellite company focused on mission critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support, is proud to announce that Sidus Space CEO and Founder Carol Craig has been chosen as a panelist for the Financial Times Investing in Space summit held on June 8-9 in London, England.
  • Hollinger will lead a discussion on the financial characteristics, value propositions, and disclosures investors look for from entrepreneurial companies.
  • Last December, Sidus Space listed its Class A common stock on the NASDAQ Capital Market via an IPO making Carol Craig the first female owner-founder of a publicly traded space company serving government and commercial space industries.
  • More than just a Satellite-as-a-Service provider, Sidus Space is a trusted Mission Partnerfrom concept to Low Earth Orbit and beyond.

LHP Engineering Solutions Partners with Juncos Hollinger Racing

Retrieved on: 
Wednesday, May 25, 2022
No, Engineering, Indianapolis Motor Speedway, Running, Hollinger, Juncos, Puerto Rico, Environment, Ilott, Solution, JHR, Transport, Detroit Grand Prix (IndyCar), Indy, Chevrolet, Industry, NTT, Partnership, Safety, Technology, LHP, Lotus 77, Indy Lights, CEO, Gasoline, Amusement arcade

INDIANAPOLIS, May 25, 2022 /PRNewswire/ -- Juncos Hollinger Racing (JHR) is pleased to announce their partnership with LHP Engineering Solutions for the 106th running of the Indianapolis 500, Chevrolet Detroit Grand Prix, and the Gallagher Grand Prix.

Key Points: 
  • INDIANAPOLIS, May 25, 2022 /PRNewswire/ -- Juncos Hollinger Racing (JHR) is pleased to announce their partnership with LHP Engineering Solutions for the 106th running of the Indianapolis 500, Chevrolet Detroit Grand Prix, and the Gallagher Grand Prix.
  • LHP Engineering Solutions will be on board the No.
  • LHP delivers state-of-the-art training, hands-on consulting and implementation, dedicated on-site resources, technology solutions, and engineering services built on the latest automotive industry standards and best practices.
  • Ricardo Juncos announced in 2021 the formation of Juncos Hollinger Racing with co-owner Brad Hollinger.

DGAP-News: Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

Retrieved on: 
Tuesday, March 15, 2022
Nexus, Epidemiology, Clinical Chemistry and Laboratory Medicine, Prognosis, CA, Critical care, The New England Journal of Medicine, Renal replacement therapy, Mortality, IVD, N-terminal prohormone of brain natriuretic peptide, CRRT, AKI, Kidney, Diagnosis, Septic shock, Biomarker, Chronic kidney disease, Hollinger, Mayo Clinic, CEO, Kidney failure, Acute kidney injury, DOI, Radboud University Nijmegen, PCT, DPP3, Disease, TSH, Medicine, Medical imaging, Pharmaceutical industry, Hospital, Patient, Troponin, Shock, Hennigsdorf, Sepsis

For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.

Key Points: 
  • For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.
  • AKI is mostly diagnosed too late for successful intervention which leads to steep mortality rates and chronic kidney disease (1,2).
  • Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers.
  • Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock.

DGAP-News: New data on innovative biomarkers used to guide the clinical management of septic patients

Retrieved on: 
Tuesday, August 31, 2021
Nexus, Acute kidney injury, Bed, Dipeptidyl peptidase-4 inhibitor, International Symposium on Endovascular Therapy, Heart, Blood, Glomerular filtration rate, Hennigsdorf, Nursing, Diagnosis, Journal of Internal Medicine, Emergency medicine, DPP3, IVD, Biomarker, Research, Endothelium, Intensive care medicine, Teaching hospital, Disease, Health, CA, Hollinger, Intermediate Care Facilities for Individuals with Mental Retardation, Clinic, Inflammation, University Hospital (Newark, New Jersey), ICU, Kidney, Education, Septic shock, Patient, High-dependency unit, Septic, Critical care, Adrenomedullin, Hypotension, Nephron, Pharmaceutical industry, Medical imaging, Hospital, Wood drying

Endothelial and kidney dysfunction are common complications in septic patients leading to organ failure and unfavorable outcomes.

Key Points: 
  • Endothelial and kidney dysfunction are common complications in septic patients leading to organ failure and unfavorable outcomes.
  • The organ-specific biomarkers bio-ADM and penKid are used in clinical routine for monitoring the endothelium and respectively kidney function in intensive care units.
  • The use of biomarkers that can facilitate a faster and better diagnosis and monitoring of sepsis progression allows clinicians to provide the best available treatment.
  • I am excited to share with the critical care community the latest insights on improving septic patients' management with the help of innovative biomarkers."